Mexico to start trial for China鈥檚 mRNA vaccine
Print Edition
MEXICO plans to start a late-stage clinical trial this month for a COVID-19 vaccine candidate developed by China using similar technology to shots from Moderna and Pfizer, foreign minister Marcelo Ebrard said on Tuesday.
The phase 3 trial for the shot from China’s Walvax Biotechnology using messenger RNA (mRNA) technology will start on May 30 and involve 6,000 volunteers, Ebrard said in a Tweet.
Walvax is working with the Academy of Military Science and Suzhou Abogen Biosciences to jointly develop the shot known as ARCoV or ARCoVax, China’s first mRNA vaccine to enter phase 3 trials. The shot could be stored at 2-8 degrees Celsius for six months, a much less stringent temperature requirement than shots from western rivals, an AMS researcher leading the vaccine project said in April.
Mexico has already received doses of other vaccines from China’s Sinovac Biotech and CanSino Biologics, and planned to order shots made by Sinopharm.
China is currently using five domestically developed vaccines in its inoculation drive, although none use mRNA technology, which contains instructions for human cells to produce proteins that mimic part of the coronavirus.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
